Naiyer Rizvi, International Study Chair and Principal Investigator at Columbia University in New York

International research collaboration explores blood-based biomarker

Using non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy.

More >>
 
https://www.ctg.queensu.ca/cctg_news/2019-new-investigator-clinical-trials-course

2019 New Investigator Clinical Trials Course

2019 New Investigator Clinical Trials Course

Mark your calendars for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.

The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of this three-day course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Innovative study advances personalized medicine for prostate cancer patients

A new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.

More >>
 

Planned trials

ALC5

Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)

More >>

BRC7

INSIGNA: Firstline Immunotherapy alone or in Combination with Chemo in Induction/Maintenance or Post Progression in Adv NSCLC with Immunobiomarker SIGNature-driven Analysis

More >>

CRC9

Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca

I238

Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity

More >>

LY18

A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

More >>

MAC25

Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Cancer

More >>

MAC26

Testing the Addition of the Study Drug Olaparib to the Usual Radiotherapy in Inflammatory Breast Cancer Patients

More >>

Recently activated

ALC6

Efficacy of the Addition of Inotuzumab Ozogamicin to Frontline Therapy in Young Adults with Precursor B-Cell ALL

More >>

BL13

Trimodality Therapy With/out Durvalumab to Treat Patients with Muscle-Invasive Bladder Cancer

More >>

HN10

Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal SCC

More >>

HNC2

Radiotherapy with Concurrent MEDI4736 vs Radiotherapy with Concurrent Cetuximab in Pts with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

More >>

I237

A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer

More >>

MAC24

MK-3475 for Triple Receptor-Negative Breast Cancer with >/= 1 cm Residual Invasive Cancer or Positive Lymph Nodes After Neoadjuvant Chemotherapy

More >>

PR20

Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery. The randomized phase III clinical trial was sponsored by the academic cancer research groups of UNICANCER, in Paris, France and the Canadian Cancer Trials Group (CCTG). The results show that the risk of cancer recurring in post-operative pancreatic cancer patients was reduced by almost 50% with the mFOLFIRINOX chemotherapy combination.

More >>
 
Pancreatic cancer patient Susan Stewart with her family, she enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial

New pancreatic cancer trial provides hope to BC family

An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.

More >>
 

Publications

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219 (ONLINE)

Lung Cancer , 2019
Melosky B;Bradbury P;Tu D;Florescu M;Reiman A;Nicholas G;Basappa N;Rothenstein J;Goffin JR;Laurie SA;Wheatley-Price P;Leighl N;Goss G;Reaume MN;Butts C;Murray N;Card C;Ko J;Blais N;Gray S;Lui H;Brown-Walker P;Kaurah P;Prentice LM;Seymour L;

More >>

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis

J Clin Oncol 37: 1102 - 1110, 2019
Litiere S;Isaac G;de Vries EGE;Bogaerts J;Chen A;Dancey J;Ford R;Gwyther S;Hoekstra O;Huang E;Lin N;Liu Y;Mandrekar S;Schwartz LH;Shankar L;Therasse P;Seymour L;

More >>

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC)

J Clin Oncol 37, 2019
Chen EX;Jonker DJ;Kennecke HF;Berry SR;Couture F;Ahmad CE;Goffin JR;Kavan P;Harb M;Colwell B;Samimi S;Samson B;Abbas T;Aucoin N;Aubin F;Koski SL;Wei AC;Magoski NM;Tu D;O'Callaghan CJ;

More >>

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/ Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer

Clin Lung Cancer 20: 66 - 73, 2019
Seymour L;Le Teuff G;Brambilla E;Shepherd FA;Soria JC;Kratzke R;Graziano S;Douillard JY;Rosell R;Reiman A;Lacas B;Lueza B;viel-Ronen S;McLeer A;Le Chevalier T;Pirker R;Filipits M;Dunant A;Pignon JP;Tsao MS;

More >>

Outcomes of Older Patients(>= 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20

Clinical Colorectal Cancer 18: e140 - e149, 2019
Wells JC;Tu D;Siu LL;Shapiro JD;Jonker DJ;Karapetis CS;Simes J;Liu G;Price TJ;Tebbutt NC;O'Callaghan CJ;

More >>

Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes

Clinical Trials 16: 14 - 17, 2019
Hay AE;Pater JL;Corn E;Han L;Camacho X;O'Callaghan C;Chong N;Bell EN;Tu D;Earle CC;

More >>

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis (ONLINE)

Leuk Lymphoma : 1 - 8, 2019
Al-Mansour Z;Cook JR;Constine LS;Couban S;Stewart DA;Shea TC;Porcu P;Winter JN;Kahl BS;Smith SM;Marcellus DC;Barton KP;Mills GM;LeBlanc M;Rimsza LM;Forman SJ;Leonard JP;Fisher RI;Friedberg JW;Stiff PJ;

More >>

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218

Pediatr Blood Cancer 66: e27540, 2019
Deyell RJ;Wu B;Rassekh SR;Tu D;Samson Y;Fleming A;Bouffet E;Sun X;Powers J;Seymour L;Baruchel S;Morgenstern DA;

More >>